Does it all ADA up? Adalimumab for ulcerative colitis

被引：3
|
作者：
Travis, Simon [1 ]
机构：
[1] John Radcliffe Hosp, Translat Gastroenterol Unit, Oxford OX3 9DU, England
来源：
GUT | 2011年 / 60卷 / 06期
关键词：
ACTIVITY INDEXES; THERAPY; INFLIXIMAB; DISEASE;
D O I：
10.1136/gut.2010.233403
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：741 / 742
页数：2
相关论文
共 50 条
  • [21] Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis
    Ananthakrishnan, Ashwin N.
    Cagan, Andrew
    Cai, Tianxi
    Gainer, Vivian S.
    Shaw, Stanley Y.
    Savova, Guergana
    Churchill, Susanne
    Karlson, Elizabeth W.
    Kohane, Isaac
    Liao, Katherine P.
    Murphy, Shawn N.
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (04) : 880 - 885
  • [22] Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis
    Spoendlin, Julia
    Desai, Rishi J.
    Franklin, Jessica M.
    Glynn, Robert J.
    Payne, Emma
    Schneeweiss, Sebastian
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (04) : 874 - 884
  • [23] Histological Remission in Ulcerative Colitis in Deep Remission under Treatment with Adalimumab
    Tursi, Antonio
    Nenna, Rosanna
    Musci, Giovanni
    Elisei, Walter
    Picchio, Marcello
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2021, 30 (01) : 55 - 58
  • [24] Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
    Xie F.
    Blackhouse G.
    Assasi N.
    Gaebel K.
    Robertson D.
    Goeree R.
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [25] Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
    Garcia-Bosch, Orlando
    Gisbert, Javier P.
    Canas-Ventura, Alex
    Merino, Olga
    Cabriada, Jose L.
    Garcia-Sanchez, Valle
    Gutierrez, Ana
    Nos, Pilar
    Penalva, Mireia
    Hinojosa, Joaquin
    Garcia-Planella, Esther
    Munoz, Fernando
    Calvet, Xavier
    Panes, Julian
    JOURNAL OF CROHNS & COLITIS, 2013, 7 (09) : 717 - 722
  • [26] Adalimumab in active ulcerative colitis: A "real-life" observational study
    Armuzzi, Alessandro
    Biancone, Livia
    Daperno, Marco
    Coli, Alessandra
    Pugliese, Daniela
    Annese, Vito
    Aratari, Annalisa
    Ardizzone, Sandro
    Balestrieri, Paola
    Bossa, Fabrizio
    Cappello, Maria
    Castiglione, Fabiana
    Cicala, Michele
    Danese, Silvio
    D'Inca, Renata
    Dulbecco, Pietro
    Feliciangeli, Giuseppe
    Fries, Walter
    Genise, Stefania
    Gionchetti, Paolo
    Gozzi, Stefano
    Kohn, Anna
    Lorenzetti, Roberto
    Milla, Monica
    Onali, Sara
    Orlando, Ambrogio
    Papparella, Luigi Giovanni
    Renna, Sara
    Ricci, Chiara
    Rizzello, Fernando
    Sostegni, Raffaello
    Guidi, Luisa
    Papi, Claudio
    DIGESTIVE AND LIVER DISEASE, 2013, 45 (09) : 738 - 743
  • [27] Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
    Armuzzi, Alessandro
    Pugliese, Daniela
    Nardone, Olga Maria
    Guidi, Luisa
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 289 - 296
  • [28] An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
    Kawalec, Pawel
    Pilc, Andrzej
    ARCHIVES OF MEDICAL SCIENCE, 2016, 12 (05) : 1097 - 1109
  • [29] Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States
    Sandborn, William J.
    Sakuraba, Atsushi
    Wang, Anthony
    Macaulay, Dendy
    Reichmann, William
    Wang, Song
    Chao, Jingdong
    Skup, Martha
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (07) : 1233 - 1241
  • [30] Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
    Gies, N.
    Kroeker, K. I.
    Wong, K.
    Fedorak, R. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (04) : 522 - 528
12345